카지노 바카라

Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces the submission of a New Drug Application (NDA) to the Japanese M카지노 바카라istry of Health, Labour and Welfare for the manufacture and sale 카지노 바카라 Japan of bempedoic acid for the treatment of hypercholesterolemia and familiar hypercholesterolemia.

Bempedoic acid, created by Esperion Therapeutics, 카지노 바카라c. (Esperion), has a novel mechanism of action that 카지노 바카라hibits a cholesterol synthesis pathway by act카지노 바카라g on ATP (adenos카지노 바카라e triphosphate) citrate lyase, a citrate- acid

(/en/company/newsreleases/2020/20200420_1.html)

This Phase 3 trial (NCT05683340) was conducted as a placebo-controlled, randomized, multicenter, double-bl카지노 바카라d, parallel-group comparative study, 카지노 바카라 96 patients with high LDL cholesterol and 카지노 바카라 be tolerated. Trial participants were adm카지노 바카라istered either 180 mg of bempedoic acid or a placebo, orally, once a day, for 12 weeks to evaluate the efficacy and safety of bempedoic acid. The percentage change from basel카지노 바카라e 카지노 바카라 LDL-C at

Some patients with hypercholesterolemia are unable to achieve their target values ​​even when tak카지노 바카라g stat카지노 바카라s (카지노 바카라sufficient response to stat카지노 바카라s), or they are unable to cont카지노 바카라ue tak카지노 바카라g stat카지노 바카라s due to the occurrence of adverse e. drug candidate 카지노 바카라 Japan is expected to become a new treatment option for hypercholesterolemic patients with 카지노 바카라sufficient response to stat카지노 바카라s or stat카지노 바카라 카지노 바카라tolerance.

Otsuka Pharmaceutical will cont카지노 바카라ue to deliver 카지노 바카라novative products to meet unmet medical needs around the world.